Callan Family Office LLC Takes Position in DexCom, Inc. (NASDAQ:DXCM)

Callan Family Office LLC purchased a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 3,061 shares of the medical device company’s stock, valued at approximately $238,000.

Other large investors have also recently modified their holdings of the company. Blue Whale Capital LLP boosted its position in shares of DexCom by 91.9% during the 3rd quarter. Blue Whale Capital LLP now owns 236,000 shares of the medical device company’s stock valued at $15,821,000 after acquiring an additional 113,000 shares during the last quarter. Brooktree Capital Management bought a new stake in shares of DexCom during the 3rd quarter valued at about $683,000. Motley Fool Asset Management LLC boosted its position in shares of DexCom by 168.7% during the 3rd quarter. Motley Fool Asset Management LLC now owns 272,622 shares of the medical device company’s stock valued at $17,993,000 after acquiring an additional 171,150 shares during the last quarter. Watts Gwilliam & Co. LLC bought a new stake in shares of DexCom during the 4th quarter valued at about $3,334,000. Finally, Congress Asset Management Co. boosted its position in shares of DexCom by 5,456.9% during the 4th quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company’s stock valued at $105,529,000 after acquiring an additional 1,332,522 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on DXCM. Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and boosted their target price for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. Canaccord Genuity Group boosted their price objective on shares of DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a report on Friday, February 14th. Wells Fargo & Company reaffirmed an “overweight” rating on shares of DexCom in a report on Saturday. Redburn Atlantic raised shares of DexCom from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. Finally, Baird R W raised shares of DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Four equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, DexCom has a consensus rating of “Moderate Buy” and a consensus target price of $99.82.

DexCom Stock Performance

Shares of NASDAQ:DXCM opened at $70.26 on Wednesday. The company has a market cap of $27.46 billion, a price-to-earnings ratio of 49.13, a price-to-earnings-growth ratio of 2.30 and a beta of 1.28. The company has a 50-day moving average price of $84.53 and a 200-day moving average price of $76.98. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. As a group, equities analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

Insider Buying and Selling

In related news, CEO Kevin R. Sayer sold 33,359 shares of the stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the completion of the transaction, the chief executive officer now directly owns 319,037 shares of the company’s stock, valued at $27,727,505.67. This represents a 9.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Jereme M. Sylvain sold 7,000 shares of the stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $73.83, for a total transaction of $516,810.00. Following the completion of the transaction, the executive vice president now directly owns 135,482 shares of the company’s stock, valued at approximately $10,002,636.06. The trade was a 4.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 45,083 shares of company stock valued at $3,826,604 over the last three months. Corporate insiders own 0.30% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.